What this means
The study looked at how safe UBX1325 is and how well people handle it when given as a repeat eye injection. This is a trial record, and the source does not say what the results showed.
Plain-English summary written by an AI model from the registry listing.
- Status
- Completed
- Who can join
- Ages 50 and over
- Where
- 14 sites, including California, Colorado, Florida
The science
- Registered title
- Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)
- Trial ID
- NCT05275205 ↗
- Phase
- PHASE 2
- Study type
- interventional
- Conditions
- Neovascular Age-related Macular Degeneration
- What is tested
- UBX1325 injection 50 μL, EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Sponsor
- Unity Biotechnology, Inc.
- Ages
- 50 Years to no maximum
- Dates
- First posted Mar 11, 2022 · updated Aug 7, 2024
Registry summary
This study is intended to assess safety, tolerability and biological activity of a repeat IVT injection of UBX1325 in patients with wet AMD.
Sites (14)
- Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
- Salehi Retina Institute, Huntington Beach, California, United States
- Advanced Vision Research Institute, Longmont, Colorado, United States
- Rand Eye Institute, Deerfield Beach, Florida, United States
- Retina Vitreous Associates of Florida, St. Petersburg, Florida, United States
- University Retina and Macula Associates, Lemont, Illinois, United States
- Illinois Eye Center, Peoria, Illinois, United States
- Midwest Eye, Carmel, Indiana, United States
- Mayo Clinic-Rochester, Rochester, Minnesota, United States
- Sierra Eye Associates, Reno, Nevada, United States
- EyeHealth Northwest, Portland, Oregon, United States
- Retina Research Institution of Texas, Abilene, Texas, United States
- Valley Retina Institute, McAllen, Texas, United States
- Austin Retina Associates, Round Rock, Texas, United States
More aging trials in these states
California · Colorado · Florida · Illinois · Indiana · Minnesota · Nevada · Oregon · Texas